Education
About Us
Working with TipRanks
Follow Us
Techno Medica Co., Ltd. (JP:6678)
:6678
6678 Stock Chart & Stats
¥2245.00
-¥13.00(-0.72%)
At close: 4:00 PM EST
¥2245.00
-¥13.00(-0.72%)
Day’s Range― - ―
52-Week Range¥1,580.00 - ¥2,787.00
Previous CloseN/A
Volume3.70K
Average Volume (3M)5.40K
Market Cap
¥20.55B
Enterprise Value¥8.12B
Total Cash (Recent Filing)¥8.67B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)15.1
Beta0.59
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.02%
Share Statistics
EPS (TTM)37.13
Shares Outstanding8,760,000
10 Day Avg. Volume4,730
30 Day Avg. Volume5,400
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)0.84
Price to Sales (P/S)1.23
P/FCF Ratio12.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero Debt Balance SheetAn entirely debt-free balance sheet materially lowers financial risk and increases resilience through cycles. This structural strength provides optionality for capital allocation (R&D, capex, dividends, M&A) without refinancing risk, supporting durable operational continuity.
High Gross MarginsSustained gross margins near 50% reflect durable product-level economics in in-vitro diagnostics and indicate pricing power or cost-effective manufacturing. Stable margin structure supports long-term profitability even if top-line growth slows, aiding reinvestment and margin recovery.
Strong FCF ConversionFree cash flow roughly matching net income demonstrates high earnings quality and reliable cash generation. Consistent FCF enables self-funding of operations and reinvestment, improving strategic flexibility for product development and capital expenditures over the medium term.
Bears Say
Revenue DeclineA year-over-year revenue contraction signals potential demand softness or product-mix pressures in key markets. Persistent or repeat declines would erode scale advantages, limit margin leverage, and constrain the ability to invest behind growth initiatives over the next several quarters.
Margin CompressionA material drop in net margin indicates rising costs or deteriorating product mix that reduces profitability per unit of revenue. If structural, margin compression can weaken return on capital and slow reinvestment capacity, making it harder to sustain R&D and competitive positioning long term.
Volatile Cash FlowUneven FCF and modest operating cash flow versus revenue suggest working-capital swings or inconsistent cash conversion. This variability raises uncertainty about financing flexibility for sustained investment or payouts and could limit the firm's ability to respond to strategic opportunities consistently.
Techno Medica Co., Ltd. News
6678 FAQ
What was Techno Medica Co., Ltd.’s price range in the past 12 months?
Techno Medica Co., Ltd. lowest stock price was ¥1580.00 and its highest was ¥2787.00 in the past 12 months.
What is Techno Medica Co., Ltd.’s market cap?
Techno Medica Co., Ltd.’s market cap is ¥20.55B.
When is Techno Medica Co., Ltd.’s upcoming earnings report date?
Techno Medica Co., Ltd.’s upcoming earnings report date is May 13, 2026 which is in 64 days.
How were Techno Medica Co., Ltd.’s earnings last quarter?
Techno Medica Co., Ltd. released its earnings results on Feb 04, 2026. The company reported ¥37.13 earnings per share for the quarter, beating the consensus estimate of N/A by ¥37.13.
Is Techno Medica Co., Ltd. overvalued?
According to Wall Street analysts Techno Medica Co., Ltd.’s price is currently Overvalued.
Does Techno Medica Co., Ltd. pay dividends?
Techno Medica Co., Ltd. pays a Annually dividend of ¥68 which represents an annual dividend yield of 3.02%. See more information on Techno Medica Co., Ltd. dividends here
What is Techno Medica Co., Ltd.’s EPS estimate?
Techno Medica Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Techno Medica Co., Ltd. have?
Techno Medica Co., Ltd. has 8,760,000 shares outstanding.
What happened to Techno Medica Co., Ltd.’s price movement after its last earnings report?
Techno Medica Co., Ltd. reported an EPS of ¥37.13 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.143%.
Which hedge fund is a major shareholder of Techno Medica Co., Ltd.?
Currently, no hedge funds are holding shares in JP:6678
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Techno Medica Co., Ltd.
Techno Medica Co., Ltd. engages in the research and development, manufacture, sale, import, and export of in-vitro diagnostic analyzers in Japan. The company offers test tube preparation, automatic urine aliquot, RFID specimen management, and RFID blood transfusion management, as well as blood gas, electrolyte, Erythrocyte Sedimentation Rate, nutrient, sugar and acid, and urine chemistry analyzers; electronic medical charts and pre-analytical instruments; and consumables and after sales services. Techno Medica Co., Ltd. was incorporated in 1987 and is headquartered in Yokohama, Japan.
Technical Analysis
PHC Holdings Corp.
―
Eiken Chemical Co., Ltd.
―
Nihon Kohden Corporation
―
Japan Medical Dynamic Marketing, Inc.
―
Koken Ltd.
―
Options Prices
Currently, No data available
---